Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
9 pending office actions • 6 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 15 patents granted in the last 365 days
Deciphera Pharmaceuticals LLC currently manages 9 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 6 distinct art units, suggesting a specialized but multi-faceted approach to their pharmaceutical intellectual property. The prosecution work involves 9 distinct examiners, which indicates that each pending action is being handled by a different individual at the patent office.
PAK, JOHN D is identified as the busiest examiner for this portfolio, though he is currently only managing 1 pending office action. This distribution shows that no single examiner holds a concentrated portion of the company's active matters. For practitioners, this means that prosecution strategies must be tailored to the specific preferences and histories of 9 different examiners rather than focusing on a primary contact.
The presence of 6 distinct art units for only 9 pending office actions highlights a diverse range of technical classifications within the Biotechnology & Pharmaceuticals sector. This breadth requires a legal team capable of navigating various examination standards across different specialized units. Because each of the 9 examiners is only handling 1 action, there is no opportunity to leverage a relationship with a single examiner to resolve multiple pending matters simultaneously.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (44%) |
| Double-patenting only | 1 (11%) |
| Double-patenting + other | 2 (22%) |
| Multi-statute (no §101) | 2 (22%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, JOHN D | 1 | 52.4% | +37.7% |
| LEE, SIN J | 1 | 68.8% | +25.1% |
| KIFLE, BRUCK | 1 | 79.2% | +15.9% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +35.1% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.1% |
| KUCKLA, ANNA GRACE | 1 | 53.2% | +54.1% |
| ENGLISH, CONNOR KENNEDY | 1 | 60.0% | +51.3% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | RODRIGUEZ, RAYNA B | 12d |
| 19544595 | FORMULATIONS OF VIMSELTINIB | LEE, SIN J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18464519 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | VALENROD, YEVGENY | 24d overdue |
| 18078269 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | ENGLISH, CONNOR KENNEDY | 8d overdue |
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | RODRIGUEZ, RAYNA B | 12d |
| 18457825 | METHODS OF TREATING DISORDERS WITH ULK INHIBITORS | KUCKLA, ANNA GRACE | 42d |
| 19545401 | FORMULATIONS OF VIMSELTINIB | PAK, JOHN D | — |
| 19544595 | FORMULATIONS OF VIMSELTINIB | LEE, SIN J | — |
| 18770318 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | KIFLE, BRUCK | — |
| 18683078 | COMBINATION THERAPY USING VPS34 INHIBITORS | PECKHAM, RICHARD GRANT | — |
| Art Unit | Apps |
|---|---|
| 1628 | 3 |
| 1699 | 1 |
| 1613 | 1 |
| 1627 | 1 |
| 1626 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19545401 | FORMULATIONS OF VIMSELTINIB | PAK, JOHN D | 1699 | §103§112DP | Final Rejection | — | Pending | Feb 20, 2026 |
| 19544595 | FORMULATIONS OF VIMSELTINIB | LEE, SIN J | 1613 | §102§103§112 | Final Rejection | — | Pending | Feb 19, 2026 |
| 18770318 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | KIFLE, BRUCK | — | DP | Non-Final OA | — | Pending | Jul 11, 2024 |
| 18683078 | COMBINATION THERAPY USING VPS34 INHIBITORS | PECKHAM, RICHARD GRANT | 1627 | §102§103DP | Non-Final OA | — | Pending | Feb 12, 2024 |
| 18389888 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | SZNAIDMAN, MARCOS L | 1628 | §103 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18464519 | METHODS OF TREATING GASTROINTESTINAL STROMAL TUMORS | VALENROD, YEVGENY | 1628 | §103 | Final Rejection | 24d overdue | Pending | Sep 11, 2023 |
| 18457825 | METHODS OF TREATING DISORDERS WITH ULK INHIBITORS | KUCKLA, ANNA GRACE | 1626 | §103 | Final Rejection | 42d | Pending | Aug 29, 2023 |
| 18078269 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | ENGLISH, CONNOR KENNEDY | 1625 | §103 | Final Rejection | 8d overdue | Pending | Dec 09, 2022 |
| 17845275 | USE OF 1-[4-BROMO-5-[1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL]-2-FLUOROPHENYL]-3-PHENYLUREA AND ANALOGS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH GENETIC ABNORMALITIES IN PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA | RODRIGUEZ, RAYNA B | 1628 | §103§112 | Final Rejection | 12d | Pending | Jun 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial